Cardiac Myosin Inhibitors: Unlocking Potential to Improve Treatment in Hypertrophic Cardiomyopathy.

Keywords: cardiomyopathy, hypertrophic; cardiac myosins; drug therapy; pharmacologic actions EN cardiomyopathy, hypertrophic cardiac myosins drug therapy pharmacologic actions 700 702 3 03/02/23 20230228 NES 230228 It has been 30 years since the identification of a I MYH7 i ( -myosin heavy chain mutation) as a cause of hypertrophic cardiomyopathy (HCM) in humans. How does mavacamten fit into the current treatment paradigm for obstructive HCM patients who are still symptomatic on standard medical therapy?. [Extracted from the article]